The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study.
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc.
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc.
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
 
Christopher Michael Pieczonka
Honoraria - Dendreon
Consulting or Advisory Role - Dendreon
Speakers' Bureau - Dendreon
Research Funding - Dendreon
 
John M. Corman
No Relationships to Disclose
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Pfizer; Sanofi
 
Curtis Dunshee
Research Funding - Astellas Medivation (Inst); BHR Pharma (Inst); Churchill Pharmaceuticals (Inst); Dendreon (Inst); Eleven Biotherapeutics (Inst); Ferring (Inst); Janssen Oncology (Inst); Myovant Sciences (Inst); pfizer (Inst); Siemens (Inst)
 
Tim Van Mouwerik
Employment - Dendreon
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
 
Robert C. Tyler
Employment - Dendreon
Stock and Other Ownership Interests - Dendreon
Travel, Accommodations, Expenses - Dendreon
Other Relationship - Dendreon
 
Nancy N. Chang
Employment - Dendreon
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
 
David Quinn
No Relationships to Disclose